His main research concerns Alzheimer's disease, Pathology, Cerebrospinal fluid, Internal medicine and Dementia. Niels Andreasen has researched Alzheimer's disease in several fields, including Central nervous system disease, Degenerative disease, Gerontology, Geriatrics and Apolipoprotein E. His biological study spans a wide range of topics, including Total tau, Tau protein, Pathogenesis, Cognitive decline and Biomarker.
His Tau protein research is multidisciplinary, relying on both Endocrinology, Elisa assay and Frontotemporal dementia. His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Placebo and Neurology. His work in Dementia covers topics such as Psychiatry which are related to areas like Nootropic Agents, Memantine and Intensive care medicine.
Niels Andreasen spends much of his time researching Internal medicine, Cerebrospinal fluid, Alzheimer's disease, Pathology and Disease. His Internal medicine study deals with Endocrinology intersecting with Amyloid beta. The study incorporates disciplines such as Tau protein, Dementia, Frontotemporal dementia, Biomarker and Neurology in addition to Cerebrospinal fluid.
The Dementia study which covers Psychiatry that intersects with Intensive care medicine. His Alzheimer's disease research integrates issues from Genetics, Apolipoprotein E and Central nervous system disease, Degenerative disease. His research investigates the connection between Disease and topics such as Immunology that intersect with issues in Proteomics.
Niels Andreasen focuses on Internal medicine, Disease, Dementia, Cerebrospinal fluid and Pathology. Niels Andreasen interconnects Cerebral glucose metabolism, Endocrinology and Oncology in the investigation of issues within Internal medicine. The concepts of his Disease study are interwoven with issues in Psychiatry, Clinical trial and Intensive care medicine.
The various areas that he examines in his Dementia study include Tau protein, Neuroscience and Pathogenesis. His Default mode network research extends to the thematically linked field of Pathology. His Alzheimer's disease research is multidisciplinary, incorporating perspectives in Glycoprotein, Apolipoprotein E, Drug and Amyloid.
The scientist’s investigation covers issues in Dementia, Internal medicine, Disease, Alzheimer's disease and Pathology. His study of Cognitive decline is a part of Dementia. His Disease research incorporates elements of Psychiatry, Clinical trial and Intensive care medicine.
His research integrates issues of Memantine, Drug development, Drug and Nootropic Agents in his study of Intensive care medicine. In general Pathology study, his work on Cerebrospinal fluid often relates to the realm of Glial fibrillary acidic protein, thereby connecting several areas of interest. Niels Andreasen combines subjects such as Endocrinology, Cholinergic and Implant with his study of Tolerability.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson;Henrik Zetterberg;Oskar Hansson;Niels Andreasen.
JAMA (2009)
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
Niels Andreasen;Lennart Minthon;Pia Davidsson;Eugeen Vanmechelen.
JAMA Neurology (2001)
Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease
Niels Andreasen;Camilla Hesse;Pia Davidsson;Lennart Minthon.
JAMA Neurology (1999)
Clinical trials and late-stage drug development for Alzheimer's disease : an appraisal from 1984 to 2014
Lon S. Schneider;Francesca Mangialasche;Francesca Mangialasche;Niels Andreasen;Niels Andreasen;Howard Feldman.
Journal of Internal Medicine (2014)
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Harald Hampel;Katharina Buerger;Raymond Zinkowski;Stefan J. Teipel.
Archives of General Psychiatry (2004)
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization.
E Vanmechelen;H Vanderstichele;P Davidsson;E Van Kerschaver.
Neuroscience Letters (2000)
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Lawrence S Honig;Bruno Vellas;Michael M Woodward;Mercè Boada.
The New England Journal of Medicine (2018)
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.
Camilla Hesse;Lars Rosengren;Niels Andreasen;Pia Davidsson.
Neuroscience Letters (2001)
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.
Magnus Sjögren;Hugo Vanderstichele;Hans Ågren;Olof Zachrisson.
Clinical Chemistry (2001)
Simultaneous Measurement of β-Amyloid(1–42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology
Annika Olsson;Hugo Vanderstichele;Niels Andreasen;Geert De Meyer.
Clinical Chemistry (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Gothenburg
University of Gothenburg
Lund University
Karolinska Institute
University of Gothenburg
Karolinska University Hospital
Lund University
Karolinska Institute
Karolinska University Hospital
Maastricht University
Polytechnic University of Timişoara
Johns Hopkins University
University of Illinois at Urbana-Champaign
University of Liverpool
Uppsala University
Grenoble Alpes University
University of Georgia
Cancer Research UK London Research Institute
Friedrich-Loeffler-Institut
Hokkaido Information University
University of California, Los Angeles
Research Triangle Park Foundation
Flinders University
University of Lübeck
Columbia University
Medical University of South Carolina